Perceptive Life Sciences Master Fund buys **863,060 shares of Immatics N.V.** at **$8.69 per share**. The acquisition increases its stake to **11.4 million shares (7.6% ownership)**, alongside Perceptive Advisors LLC and Joseph Edelman. The transaction reflects growing institutional interest in Immatics’ immunotherapies and clinical pipeline.

Sep 2026Kalkine MediaNews article

Vaderis Therapeutics secures **$152.5 million in Series B funding**, co-led by Goldman Sachs Alternatives and TCGX, with additional support from Omega Funds, EQT Life Sciences, Perceptive Life Sciences, Medicxi, Kalehua Capital Partners, and existing investors Medicxi and Droia. The capital advances the company’s **Phase 3 HEROIC study**, though specific trial details remain undisclosed. Vaderis focuses on developing novel therapeutics, though the article does not specify its primary disease targets or pipeline stage.

Aug 2026Goldman Sachs Asset ManagementNews article

Anteris Technologies raises **$20 million** through a private placement of **1.84 million new shares** at **A$15 each**, a **20% discount** to its February 28, 2022, closing price. The funds are allocated to the **Perceptive Life Sciences Master Fund**, managed by Perceptive Advisors. The agreement secures capital for the company’s growth while offering investors a discounted valuation.

Mar 2022Yahoo FinanceNews article

AsclepiX Therapeutics secures **$35 million in Series A funding** led by Perceptive Xontogeny Venture Fund, with additional support from Perceptive Life Sciences Fund, Rapha Capital Management, and Barer & Son Capital. The round expands the company’s capital base to advance its therapeutic development pipeline. Existing investors also participate in the financing round.

Jun 2020BioSpaceNews article